当前位置:
首页>产品中心>单抗/多抗>Ocaratuzumab ELISA Kit|Ocaratuzumab ELISA试剂盒(靶标:)
Ocaratuzumab ELISA Kit|Ocaratuzumab ELISA试剂盒(靶标:)
- 货号:RB9TDY257078
- 价格:面议
- 点击:403
产品介绍
产品参数
| 应用 | ELISA |
|---|
| 检测方法 | Colorimetric |
|---|
| 灵敏度 | 0.156 μg/ml |
|---|
| 检测范围 | 0.31-5 μg/mL |
|---|
| 回收率 | 80-120% |
|---|
| 样本类型 | Plasma, Serum |
|---|
| 检测类型 | Quantitative |
|---|
| 稳定性和储存 | The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. |
|---|
| 运输条件 | 2-8 ℃ |
|---|
| 登录号 | P11836 |
|---|
| 背景信息 | Ocaratuzumab, previously known as AME-133v, is a humanized IgG1 type monoclonal antibody targeted at CD20 antigen, which is expressed on B-lymphocytes. Ocaratuzumab is a novel Fc-engineered monoclonal antibody designed by Applied Molecular Evolution in an attempt to induce effective antibody-dependent cell-mediated cytotoxicity (ADCC) at very low concentrations that may facilitate sub-cutaneous dosing. Libraries of antibody Fab fragment regions were generated with codon substituted variations of the antibody complementarity determining regions (CDRs) inserted into human antibody light and heavy chain germline frameworks. Then, the researchers expressed and selected mutants based on increased affinity for CD20. A variable region with increased binding activity for CD20 was selected and developed as ocaratuzumab. This drug is currently being developed by Mentrik Biotech and has been investigated in the trial for the treatment of cancer and autoimmune disorders. The pre-clinical trials of ocaratuzumab in follicular lymphoma was conducted in the United States (US) and Japan in phase I/II, and a Phase I trial was conducted in US rheumatoid arthritis patients. In addition, a phase III trial in relapsed follicular lymphoma patients is underway. Compared to rituximab, ocaratuzumab was shown to ocaratuzumab was shown to have 13 to 20 fold greater affinity for CD20 and 6 fold more potent ADCC in pre-clinical studies. The use of ocaratuzumab in other oncology and rheumatology indications has also been developed. |
|---|
| 别名 | AME-133v, LY2469298, 1169956-08-4 |
|---|
| 备注 | For Research Use Only. |
|---|
【仅供科学研究使用】
相关产品: